Hub · Peptides in Perth: Research Guide, Delivery and WA Law
Selank in Perth
Selank is a lab-made peptide with seven amino acids, written TKPRPGP. It was built from tuftsin, a natural four-amino-acid peptide. We searched Australia's October 2026 Poisons Standard (instrument F2026L01327) on 14 October 2026. It had no individual entry for Selank. A missing entry is not permission to buy or sell it in Western Australia.
A peptide is a short chain of amino acids, the small units that make proteins. Selank is a chain of seven. Its letters are TKPRPGP, and you can read them one by one. That makes Selank a good first lesson in how a peptide is described. This page is part of the Perth research peptides hub. It also links to the Perth peptide guides. It keeps each record in its own lane: the sequence, the papers, the law and the parcel. So you can see what each one shows and where it stops.
Catalogue listing: Buy Selank (research use only). This material is sold for research use only. It is not for human or animal use.
Key facts
| Common name | Selank, also written TP-7 |
|---|---|
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) |
| Parent peptide | Tuftsin (Thr-Lys-Pro-Arg) |
| Database record | PubChem record 11765600 |
| Where it was designed | Institute of Molecular Genetics, Russian Academy of Sciences (Volkova et al., 2016) |
| Poisons Standard search | None found for selank, tuftsin, TP-7 or the sequence. Group headings were not assessed (searched 14 October 2026). Instrument: Poisons Standard October 2026, F2026L01327, dated 28 September 2026 |
| TGA advisory naming | Selank is not named. The examples are BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 (TGA advisory, 13 April 2026) |
| Registered trials | A ClinicalTrials.gov search for the term selank on 14 October 2026 returned only loosely matched records, none of which contains the word Selank |
| Store listing name | Selank reference material, research use only |
What is Selank?
Selank is a lab-made peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is also written TP-7. Each three-letter code names one amino acid. In one-letter form the chain reads TKPRPGP. Volkova and colleagues (Frontiers in Pharmacology, 2016) say Selank was designed and made at the Institute of Molecular Genetics of the Russian Academy of Sciences. The Selank research guide covers the compound in more depth than this page.
Think of the chain as seven beads on a string. Each bead is one amino acid. The order of the beads is the sequence. Two chains with the same beads in a different order are different molecules. A sequence tells you what a molecule is. It does not tell you what any vial holds. That is why the questions below come after this one.
How is the Selank sequence built?
The Selank sequence is the tuftsin chain Thr-Lys-Pro-Arg followed by the tail Pro-Gly-Pro. Tuftsin is a natural peptide with four amino acids. Split the one-letter code TKPRPGP after the fourth letter. You get TKPR, which is tuftsin, and PGP, which is the tail. You can check this yourself by counting the letters and cutting at the join.
Volkova and colleagues (2016) describe Selank as a seven-amino-acid chain built from tuftsin. A chain that keeps the same letters can still become a different molecule if its ends change. Vanhee and colleagues (Drug Testing and Analysis, 2020) used chemical analysis to tell Selank apart from two modified forms. N-acetyl Selank has a small cap on the front end of the chain. N-acetyl Selank amidate has a change at both ends. Their paper did not compare how the forms act in people. The Selank hub lists the related guides.
What do the Selank papers show?
The Selank papers cited here describe the molecule and measure gene activity in rat brain tissue. Volkova and colleagues (Frontiers in Pharmacology, 2016) used rats and gave Selank as a diacetate salt, which is a partner chemical that travels with the peptide. One hour after Selank, 29 genes met the study's rules for a change. At three hours, 17 did. These are animal gene measurements. They do not show a result in people.
Ten rats were assigned to each group, and five were sampled at each time point. Their tissue was pooled. A gene measurement is not a direct reading of anything a person would notice. A result in a rat does not become a result in a person because both studies name the same molecule. Doyno and White (Journal of Clinical Pharmacology, 2021) call Selank 'poorly studied'. This page reports no result in people and gives no amounts or directions for use.
Evidence limits
What can these records leave unresolved?
These records leave open whether any person may lawfully buy, sell or import Selank. A paper describes a molecule. A dated search records what one document held on one day. A tracking link follows a parcel. No record answers the question that belongs to another. A search of ClinicalTrials.gov for the term selank on 14 October 2026 returned only loosely matched records. None of them contains the word Selank.
Read the records as separate documents. Each was written for its own purpose. A science paper cannot approve a supply. A missing entry in a legal list is not a statement of permission. A parcel route cannot settle a question of law. Each of these sentences marks a limit on what a record can carry. None is a new legal finding.
Is Selank legal in Western Australia?
The search recorded here cannot say whether Selank is legal in Western Australia. On 14 October 2026 we searched the October 2026 Poisons Standard, instrument F2026L01327, dated 28 September 2026. The record reads: "None found for selank, tuftsin, TP-7 or the sequence. Group headings were not assessed (searched 14 October 2026)." That is a name result for one document on one date. A missing entry is not permission.
The Poisons Standard sorts substances into schedules, which are tiers of control. Group headings were not assessed, so this page draws no conclusion about them. We have not checked the position since 14 October 2026. The WA scheduling explainer sets out the two layers of law that apply, federal and Western Australian. It cannot stand in for this dated search. This page gives no legal advice.
Why do the TGA notices matter beside an absent entry?
The TGA notices matter because they are a different record from the Poisons Standard. The Therapeutic Goods Administration advisory of 13 April 2026 lists BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as examples of unapproved peptide products. It does not name Selank. That is a fact about the list, not a statement of permission. The advisory covers importing, supplying and advertising unapproved peptide products.
The advisory says a research-use-only label does not change a product's regulatory status. It gives no right to import. It does not remove duties around advertising or supply. It adds that state and territory laws may place further controls on sale and supply. This page offers no legal advice and implies no exemption.
Which part of the Perth journey can a tracking record answer?
A tracking record answers where a parcel is and when it may arrive. It does not show identity, purity or legal permission. The store's shipping page says orders leave Perth, Western Australia, after payment has cleared, sent by Australia Post or CouriersPlease. A tracking email follows when the order is packed and handed over. The dispatch and tracking record is the whole of what this page draws on for the journey.
The shipping page says the outer packaging is plain and unbranded. The route is domestic and online-only. These notes describe the store at Form Laboratories in Perth. Nothing in them gives an address, opening hours or a place to visit. The listing for this material is Selank reference material, sold for research use only.
Comparison
Four records, four questions. Each column is one record. Each row states what it is drawn from, the question it answers and the question it cannot answer. The table separates the records. It does not rank them or compare products.
| Record detail | Sequence | Research papers | Dated legal records | Parcel tracking |
|---|---|---|---|---|
| Drawn from | Volkova et al., Frontiers in Pharmacology, 2016; PubChem record 11765600 | Volkova et al., 2016; Vanhee et al., Drug Testing and Analysis, 2020; Doyno and White, 2021 | Poisons Standard search of 14 October 2026; TGA advisory, 13 April 2026 | The store's shipping page: dispatch from Perth, tracking email after handover |
| Question it answers | Which seven amino acids make up Selank, and which four come from tuftsin | What the researchers measured in their own study | What one document held on one date, and which examples the TGA named | Where a parcel is after handover |
| Question it cannot answer | What any vial contains | What happens in people, or what any supply contains | Whether a sale is permitted, or whether the position changed after the check date | What the contents are, or what the law says |
FAQ
Did the October 2026 Poisons Standard search find an individual entry for Selank?
No individual entry was found. We searched F2026L01327, the October 2026 instrument, on 14 October 2026. The record reads: "None found for selank, tuftsin, TP-7 or the sequence. Group headings were not assessed (searched 14 October 2026)." A missing entry is not permission. We have not confirmed the position since that day.
What is the difference between Selank and tuftsin?
Selank is tuftsin with a tail added. Tuftsin is the four-amino-acid chain Thr-Lys-Pro-Arg. Selank is the seven-amino-acid chain Thr-Lys-Pro-Arg-Pro-Gly-Pro. The three extra units, Pro-Gly-Pro, come after the tuftsin block.
Has the TGA named Selank as an unapproved peptide product?
The TGA advisory of 13 April 2026 does not name Selank. Its examples are BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295. The advisory says a research-use-only label does not change a product's regulatory status. State and territory laws may add controls.
Is there a registered trial of Selank?
None was found. A ClinicalTrials.gov search for the term selank on 14 October 2026 returned only loosely matched records. None of them contains the word Selank. This covers one registry on one day, not every registry.
More in this hub
Peptides in Perth: Research Guide, Delivery and WA Law
- Peptides in Perth: 20 Questions, Answered
- Ordering Peptides From Perth Instead of Importing
- Peptide Delivery Times From Perth, State by State
- Research Peptides Across Western Australia
- Freeze-Dried Peptides and a Perth Summer: What Studies Report on Heat, Light and Water
- Are peptides legal in Western Australia and Perth?
- How to Choose a Research Peptide Supplier in Perth
- Perth Based Peptide Company: Research Stock and Dispatch
- How to Check a Peptide Supplier Is Legit
- Australian Peptide Supplier with Third-Party Testing and COAs
- Australian Peptide Suppliers Compared: A Research Buyer Checklist
- Retatrutide in Perth: Research Records and WA Status
- Tirzepatide in Perth: Research Records and WA Status
- Tesamorelin in Perth: Research Records and WA Status
- Semax in Perth: Research Records and WA Status
- GHK-Cu in Perth: Research Records and WA Status
- TB-500 in Perth: the Thymosin Beta-4 Fragment
- BPC-157 in Perth: Scheduling, Research and Dispatch
- CJC-1295 in Perth: No DAC, Ipamorelin and TGA Status
- MOTS-c in Perth: a Peptide Written in Mitochondrial DNA
- NAD+ in Perth: What It Is, and Why It Is Not a Peptide
- How to Read a Peptide Trial on the ANZCTR
Citations
3 sourcesVolkova A et al. Frontiers in Pharmacology. 2016;7:31.
doi:10.3389/fphar.2016.00031Vanhee C, Francotte A, Janvier S, Deconinck E Drug Testing and Analysis. 2020;12(3):371-381.
doi:10.1002/dta.2717Doyno CR, White CM Journal of Clinical Pharmacology. 2021;61(Suppl 2):S114-S128.
doi:10.1002/jcph.1922
Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.